U.S. court weighs whether to let Actavis drop Alzheimer's drug
April 13, 2015 at 14:42 PM EDT
NEW YORK, April 13 (Reuters) - Actavis Plc urged a U.S. appeals court on Monday to allow it to discontinue a top-selling Alzheimer's drug in favor of a pricier extended-release version, a move that New York's attorney general has said would suppress generic competition.
